New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The incidence of urolithiasis (kidney/renal stones) depends on geographic, climatic, ethnic, dietary, and genetic factors. Assistant Professor Chua Wei Jin, Senior Consultant, Department of Urology at the National University Hospital in Singapore discusses with Audrey Abella why urolithiasis is an important healthcare problem that requires attention.
Adding the PD-L1 inhibitor atezolizumab to first-line platinum-based chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic urothelial carcinoma (mUC), according to the IMvigor130* study presented at the ESMO Congress 2019.
Men with metastatic castration-resistant prostate cancer (mCRPC) derived significantly greater clinical benefit from cabazitaxel vs the androgen receptor-targeted agents (ARTA) abiraterone or enzalutamide, according to the results of the CARD* trial presented at ESMO 2019.
There appears to be no pressing need for men with prostate cancer to undergo radiotherapy immediately after surgery, according to a recent study presented at the 2019 Congress of the European Society of Medical Oncology (ESMO 2019).
Testosterone replacement therapy (TRT) in men with hypogonadism was associated with an increased risk of ischaemic stroke, transient ischaemic attack (TIA), and myocardial infarction (MI), particularly in the first 2 years of use, a study shows.
Cabozantinib was no better than the combination of mitoxantrone and prednisone for pain relief in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, according to the findings of the COMET-2* trial.